Hypersensitivity adverse drug reactions in children: Pathophysiology and therapeutic implications

Current Therapeutic Research - Clinical and Experimental

Volumn 62, Issue 12, 2001, Pages 913-929

  Rieder, Michael J ^a,b  

^a Childrens Hospital of Western Ontario   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Adverse drug reactions; Children; Hypersensitivity; Pathophysiology

Indexed keywords

DRUG;

CHILD; CHILDHOOD DISEASE; CONFERENCE PAPER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; HUMAN; IMMUNOPATHOGENESIS; MEDLINE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TREATMENT PLANNING;

EID: 0035699596     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(01)80095-3     Document Type: Article

References (71)

1. Adverse drug reactions remain a major cause of death
2. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
3. Counting the costs of drug-related adverse events
4. Drug usage and adverse drug reactions in paediatric patients
5. A prospective study of adverse drug reactions as a cause of admission to a paediatric hospital
6. Adverse drug reactions (ADRs) in hospitalized pediatric patients: A prospective study
7. A prospective study of adverse drug reactions in hospitalized children
8. Epidemiology of adverse drug reactions in the newborn
9. Clinical toxicology in the neonatal intensive care unit
10. Drug allergy and protocols for management of drug allergies
11. The therapeutic revolution
12. Classification of allergic reactions responsible for drug hypersensitivity reactions
13. The role of reactive drug metabolites in immune-mediated adverse drug reactions
14. Immunological principles of adverse drug reactions: The initiation and propagation of immune responses elicited by drug treatment
15. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk
16. A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience
17. Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis
18. Serum sickness-like reactions to cefaclor: Role of hepatic metabolism and individual susceptibility
19. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity
20. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro “rechallenge” with hydroxylamine metabolites
21. Idiosyncratic drug reactions: The reactive metabolite syndromes
22. Idiosyncratic drug reactions: Metabolic bioactivation as a pathogenic mechanism
23. Mechanisms of unpredictable adverse drug reactions
24. Role of drug disposition in drug hypersensitivity: A chemical, molecular and clinical perspective
25. The immunologic and metabolic basis of drug hypersensitivities
26. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase
27. Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions
28. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man
29. The cytotoxicity of clozapine metabolites: Implications for predicting clozapine-induced agranulocytosis
30. Time course of toxicity of reactive sulfonamide metabolites
31. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes
32. Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection
33. Carbamazepine-hypersensitivity: Assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine
34. Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reaction arene oxide(s)
35. Serum sickness-like reaction to cefaclor: Lack of in vitro cross-reactivity with loracarbef
36. Drug disposition and drug hypersensitivity
37. Drug-protein conjugation and its immunological consequences
38. Mechanisms of drug reactions: The metabolic track
39. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis
40. Biotransformation of halothane, enflurane, isoflurane and desflurane to trifluoroacetylated liver proteins: Association between protein acylation and hepatic injury
41. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions
42. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions
43. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity
44. Metabolic activation in drug allergies
45. Toxicity of sulfonamide reactive metabolites in HIV-infected, HTLV-infected and noninfected cells
46. In vivo and in vitro testing for adverse drug reactions
47. Studies on the sensitization of animals with simple chemical compounds
48. Covalent and noncovalent interactions in acute lethal cell injury caused by chemicals
49. Current trends in drug-induced autoimmunity
50. Lymphocyte activation in allergic reactions elicited by small-molecular-weight compounds
51. T cell mediated immunity
52. Role of T cells in drug allergies
53. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alpha beta T cell clones
54. Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human alpha beta+ T cell clones
55. Immunopharmacology and adverse drug reactions
56. New concepts in immunology relevant to idiosyncratic drug reactions: The “danger hypothesis” and innate immune system
57. Lymphocyte activation in cutaneous drug reactions
58. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides
59. Cellular toxicity of sulfamethoxazole reactive metabolites. II. Inhibition of natural killer activity in human peripheral blood mononuclear cells
60. Suppression of T-lymphocyte proliferation by sulfonamide hydroxylamines
61. Suppression of pokeweed mitogen-driven human IgM and IgG responses by the hydroxylamine of sulfamethoxazole
62. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation
63. Cytotoxicity of sulfonamide reactive metabolites: Apoptosis and selective toxicity of CD8(+) cells by the hydroxylamine of sulfamethoxazole
64. Inhibition of cytokine production and interference in IL-2 receptor mediated Jak-Stat signaling by the hydroxylamine metabolite of sulfamethoxazole
65. The expanding universe of T-cell subsets: Th1, Th2 and more
66. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins
67. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines
68. Role of viral infections in the induction of adverse drug reactions
69. Tolerance, danger and the extended family
70. Beyond self and non-self: Immunity is conversation, not a war
71. An innate sense of danger